Ablynx extends ion channel research collaboration with Merck & Co.
Merck & Co., Inc. will extend their funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a €6.5 million upfront payment and €2 million in initial research funding.
Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a €20 million upfront payment, €10.7 million in research funding and total potential milestone payments of up to €1.7 billion plus royalties.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.